• Alexanian, R., Barlogie, B. & Dixon, D. (1988) Prognosis of asymptomatic multiple myeloma. Archives Internal Medicine, 148, 19631965.
  • Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hematopoietic stem cell transplantation. British Journal of Haematology, 102, 11151123.
  • Dimopoulos, M., Moulopoulos, L., Smith, T., Delasalle, K. & Alexanian, R. (1993) Risk of disease progression in asymptomatic multipe myeloma. American Journal of Medicine, 94, 5761.
  • Dimopoulos, M., Monopoulos, L., Maniatis, A. & Alexanian, R. (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 96, 20372044.
  • Facon, T., Menard, J.F., Michaux, J.L., Euller-Ziegher, L., Bernard, J.F., Grosbois, B., Daragon, A., Azais, I., Courouble, Y., Kaplan, G., Laporte, J.P., De Gramont, A., Duclos, B., Leonard, A., Mineur, P., Delannoy, A., Jouet, J.P., Bauters, F. & Monconduit, M. (1995) Prognostic factors in low tumor mass asymptomatic multiple myeloma: a report on 91 patients. American Journal of Hematology, 48, 7175.
  • Hjorth, M., Hellquist, L., Homberg, E., Magnusson, B., Rödjer, S. & Westin, J. (1993) Initial versus deferred Melphalan-prednisone therapy for asymptomatic multiple myeloma stage I – A randomized study. European Journal of Haematology, 50, 95102.
  • Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal American Statistically Association, 53, 457481.
  • Kyle, R.A. & Greipp, P.R. (1980) Smoldering multiple myeloma. New England Journal of Medicine, 302, 13471349.
  • Kyle, R., Thernau, T., Rajkumar, V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564569.
  • Montoto, S., Bladé, J. & Montserrat, E. (2002) Monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 20872088 (Letter to the Editor).
  • Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6·633 patients from 27 randomized trials. Journal Clinical of Oncology, 16, 38323842.
  • Peto, R. & Pike, M.C. (1973) Conservation of the aproximation (O-E) /E in the logrank test for survival data or tumor incidence data. Biometrics, 29, 579584.
  • Weber, D., Dimopoulos, M., Monopoulos, L., Delasalle, K., Smith, T. & Alexanian, R. (1997) Prognostic features of asymptomatic multiple myeloma. British Journal of Haematology, 97, 810814.
  • Wisloff, F., Andersen, P. & Andersson, T.R., (1991) Incidence and follow-up of asymptomatic multiple myeloma. European Journal of Haematology, 47, 338341.